

BC Cancer Summit 2021: Forging the Path Forward

Detailed Session Agendas

This document contains the detailed agenda for all of the sessions over the three day of the Summit. Scroll through the document to review details for the whole program or to view a specific session agenda, click on the relevant link below:

Thursday, November 18, 2021:

- [TFRI BC Node Day](#)

Friday, November 19, 2021:

- [Keynotes](#)

Breakout Session – 11:00 AM

- [BC Cancer Research Stream - AM Session](#)
- [Breast Tumour Group Session](#)
- [Head and Neck Session](#)
- [Looking to the Future in Radiotherapy in BC](#)
- [Lung Radiation Oncology and SABR Clinical Trials Update - \(Radiation Oncology Only\)](#)
- [Lymphoma Tumour Group](#)
- [Metastatic Uveal Melanoma](#)
- [Nursing & Allied Health Research & KT: Operating at the intersection of science, practice and policy](#)
- [Pharmacy Oncology Session](#)
- [Sarcoma Tumour Group](#)
- [Gender Identities & Sexual Orientations: Making Cancer Care Safe for Everyone](#)

Breakout Session – 1:00 PM

- [BC Cancer Research Stream – PM Session](#)
- [Lung Cancer Update BC Cancer](#)
- [Gastrointestinal Tumour Group](#)
- [Gynecology Tumour Group](#)
- [Medical Physicist Session](#)
- [The Path to Enhanced Nursing Practice - The Role of Professional Practice Nursing in Oncology](#)
- [Optimizing physical function throughout cancer treatments: Emerging evidence Advanced topics in Psycho-oncology and Palliative Care: Artificial Intelligence, Pregnancy, Death and the Law](#)
- [Advanced topics in Psycho-oncology and Palliative Care: Artificial Intelligence, Pregnancy, Death and the Law](#)
- [Plenary: BC Cancer Awards](#)

Saturday, November 19, 2021:

- [Family Practice Oncology – GPO Day, Saturday, November 20, 2021](#)

Thursday, November 18, 2021

Terry Fox Research Institute Day and Posters

***Non- accredited session**

Thursday, November 18, 2021

8:30am – 4:00pm

Moderator: Kevin Sauve

8:30am – 4:00pm	The TFRI BC Node Research Day offers an informative and engaging program of research knowledge translation and exchange. The focus this year is the TFRI Marathon of Hope Cancer Centres Network and BC Cancer’s projects and activities in the MoHCCN. We will have presentations from each of the seven projects that comprise the launch of MoHCCN at BC Cancer, as well as a presentation from Dr. Jim Woodgett, President of TFRI, and a panel discussion to be moderated by Stuart McNish (presenter of Conversations That Matter program). We hope the day will be a robust and dynamic dialogue about cancer genomic medicine in BC and Canada.
-----------------	---

Friday, November 19, 2021

*CME accreditation pending

Plenary: Forging the Path Forward

Friday, November 19, 2021

8:30am – 10:50am

Moderator: Dr. Ursula Lee and Dr. Christine Simmons

Time	Topic	Speaker(s)
08:30am – 08:45am	2021 BC Cancer Summit welcome and conference information	Dr. Ursula Lee, Medical Oncologist, BC Cancer Summit Co-Chair Dr. Christine Simmons, Medical Oncologist BC Cancer Summit Co-Chair
	Indigenous welcome and blessing	Diane Longboat, PHSA – Indigenous Health Team
	Welcome to the BC Cancer Summit	Dr. Kim Nguyen. Chi, Chief Medical Office Heather Findlay, Chief Operating Office
Keynote 1		
08:45am – 09:30am	Equity in Health Care – No One Left Out Canada’s history in health care delivery to minorities, starting with the Residential Schools and bringing it up to date with the challenges of delivering health care to diverse communities.	The Right Honourable Beverley McLachlin Chief Justice of Canada from 2000 to 2017
Keynote 2: Bright Spots in Forging the Path Forward		
9:30 – 10:50am	9:30 > BC Cancer’s Indigenous Cancer Care Strategy	Warren Clarmont Provincial Director, Indigenous Cancer Control
	9:45 > Precision oncology Evidence Development in Cancer Treatment (PREDICT)	Dr. Cheryl Ho, Medical Oncologist Dr. Howard Lim, Medical Oncologist
	10:00 > Precision Oncology for Young People (PROFYLE)	Dr. Rebecca Deyell, , Pediatric Oncologist, BC Children’s Hospital Dr. Rod Rassekh, Pediatric Oncologist, BC Children’s Hospital

	<p>10:15 > Future Innovations in Radiotherapy: Proton Therapy and Flash Radiation</p> <p>Radiation therapy is usually delivered with four general categories of ionizing radiation: photons, electrons, protons, heavy ions. By far the majority (and all of the therapeutic radiation in BC) is delivered with electrons or photons. While these modalities are highly effective and can be used to deliver precise dose distributions delivering high doses to target tumours while sparing normal tissue, there are limitations related to the way the radiation interacts with tissue, and the anatomic relationship with the surrounding and overlapping normal tissues. Proton have some physical properties that provide greater geometric sparing of normal tissue in some situations that provide a therapeutic advantage for some clinical situation. There are increasing applications and cost effectiveness for proton therapy that will be explored. If you want to hear more about the current state in Canada, please attend.</p> <p>Regardless of the type of radiation used, external beam radiation usually delivers the radiation at a rate of a few Gray (the unit of energy deposited with the radiation) per minute. A novel form of delivering radiation. While all forms of radiation have their effect primarily by damaging DNA either directly or indirectly in both normal tissues and cancer cells. The presence of oxygen, repair proteins, and other factors at the time of the radiation can impact whether a cancer cell or a normal cell dies off. The relative rate at which radiation irreparably damages cancer cells more than normal cells leads to a therapeutic benefit (curing patients of their cancer with little or no significant side effects). Ultimately it is this balance that determines whether radiation is effective for a patient or not. Flash radiation has the potential to tip this balance in favour of better cancer control with less side effects. For how it does this and whether this is a new hope for the future, please attend our session.</p>	<p>Dr. Scott Tyldesley, Radiation Oncologist Dr. Andrew Minchinton, Senior Scientist, BC Cancer Research Institute Dr. Cheryl Duzenli, Head Medical Physics, Vancouver Centre, BC Cancer</p>
	<p>10:30 > Searching for new therapeutic targets in solid tumors: lessons from childhood cancers</p>	<p>Dr. Poul Sorensen, Distinguished Scientist, Professor, Department of Pathology, UBC</p>
<p>10:50am – 11:00am</p>	<p>Exhibitors, Posters, and Networking</p>	

Breakout Sessions – 11:00AM

BC Cancer Research Stream – AM Session

***Non- accredited session**

Friday, November 19, 2021

11:00am – 12:30pm

Moderator: Kevin Sauve

BC Cancer Research contributes to improving the lives of patients through the integration of basic biomedical research, genomics, clinical trials, health services research, cancer surveillance, population health, and the development and delivery of innovative new technology, programs, and interventions. This year, the focus is on Early Career Researchers and research trainees, with presentations about the new and innovative projects of these new and emerging investigators.

Time	Topic	Speaker(s)
11:00am – 11:30am	<i>To be confirmed</i>	Leandro Venturutti
11:30am – 12:00pm	<i>To be confirmed</i>	Ly Vu
12:00pm – 12:30 pm	<i>To be confirmed</i>	Laura Evgin

Breast Tumour Group – AM Session

Friday, November 19, 2021

11:00am – 12:30pm

Moderator: Dr. Stephen Chia

Time	Topic	Speaker(s)
11:00am – 11:05am	Opening remarks by Chair	Dr. Stephen Chia
11:05am – 11:45pm	Breast Surgical Oncology	Dr. Elaine. McKevitt
11:45pm – 12:30 pm	Breast Medical Oncology	Dr. Stephen Chia Mehrnoosh Pauls

Head & Neck Tumour Group Session

Friday, November 19, 2021

11:00am – 12:30pm

Moderator: Dr. Jonn Wu

Learning Objective:

1. Describe current multidisciplinary management of head and neck and thyroid cancers

Time	Topic	Speaker(s)
11:00am – 11:10am	Update on TORS for oropharynx	Dr. Eitan Prisman
11:10am – 11:20am	Update on Advanced H&N Squamous Cell Carcinoma and reconstruction	Dr. Eitan Prisman
11:20am – 11:30am	Update: Molecular characterization of cancers via PREDICT	Dr. Cheryl Ho
11:30am – 11:45am	Oral Cavity Cancers and Lymph Node Metastases	Kelly Liu
11:45am – 12:00pm	The Exploration of Cellular Morphology as a potential non-invasive approach for oral cancer screening	James Jeon
12:00pm – 12:10pm	Outcomes of non-surgical management for oral cavity carcinoma	Dr. Fatimah Alfaraj
12:10pm – 12:20pm	Thyroid Surgical Oncological Quality Indicators for Papillary Thyroid Cancer	Dr. Nicole Mak
12:20pm – 12:30pm	Early Stage, locally advanced well-differentiated thyroid cancer - an analysis of patients aged <55 years	Dr. Daegan Sit

Looking to the Future in Radiotherapy in BC - (This session is for members of the RT Program at BC Cancer only)

Friday, November 19, 2021

11:00am – 12:30pm

Moderator: Dr. Scott Tyldesley and Fiona Mitchell

Learning Objectives:

1. Identify why MR is needed in RT - physics
2. Discuss the radiation therapy process difference
3. the current vendors and equipment in currently available
4. Understand the clinical & technical Considerations for treatment delivery

MRI in Radiation Therapy Overview.

Time	Topic	Speaker(s)
<i>To be confirmed</i>	Overview of why MR is used in RT	Dr Scott Tyldesley, Dr. Fiona Mitchell, Dr. Steven Thomas Dr. Haley Clark
<i>To be confirmed</i>	Benefits and pitfalls	
<i>To be confirmed</i>	Process changes	
<i>To be confirmed</i>	BC Cancer future	

Lung Radiation Oncology and SABR Clinical Trials Update - (This session is for Radiation Oncologists only)

Friday, November 19, 2021

11:00am – 12:30pm

Moderator: Dr. Benjamin Mou

Learning Objectives:

1. Review the goals of radiotherapy clinical trials in the setting of metastatic disease
2. Discuss the logistics of SABR clinical trials in BC
3. Review the role of SABR for oligometastatic and oligoprogressive disease
4. Explore clinical trial opportunities for poor performance status patients with brain metastases

Clinical trials are paramount to establish changes to medical practice. Ongoing advancements in radiotherapy technology continue to provide new opportunities to improve patient outcomes. This session will explore the role of radiotherapy clinical trials for patients with various settings of metastatic disease. Stereotactic ablative radiotherapy (SABR) plays an important role in the aggressive treatment of patients with limited sites of metastases, potentially modifying the disease course for many patients. Current and upcoming SABR clinical trials in BC will be discussed along with updates on its use provincially. Finally, poor performance status patients are often excluded from clinical trials yet represent a sizable proportion of real-world patients. A new provincial trial studying this patient population will be explored.

Time	Topic	Speaker(s)
11:00am – 11:10am	Radiotherapy Clinical Trials in Metastatic Disease: Past Successes and Future Goals	Dr. Benjamin Mou
11:10 am – 11:50am	SABR Clinical Trials in BC: Where We Are and Where We Should Go Next	Dr. Rob Olson
11:50 am – 12:10pm	Oligometastases and Oligoprogression Evidence: What is Accruing and What is Reported	Dr. Devin Schellenberg
12:10pm – 12:30pm	RAPPLE: A Clinical Trial of RAPid SimPLE Targeted Radiotherapy for Brain Metastases	Dr. Alan Nichol

Lymphoma Tumour Group

Friday, November 19, 2021

11:00am – 12:30pm

Moderator: Dr. Laurie Sehn and Dr. Christian Steidl

Time	Topic	Speaker(s)
11:00	Genomic Analysis of Mature B-cell Lymphomas (GAMBL)	Ryan Morin
<i>To be confirmed</i>	Hot Topics in Multiple Myeloma	Chris Venner
<i>To be confirmed</i>	CLL in BC: What's on the horizon for 2022	Alina Gerrie

Metastatic Uveal Melanoma

Friday, November 19, 2021

11:00am – 12:30pm

Moderator: Dr. Katherine Paton

More information to come...

Nursing & Allied Health Research & KT: Operating at the intersection of science, practice and policy

Friday, November 19, 2021

11:00am – 12:30pm

Moderator: Andrea Knox

As a leading cancer research organization, BC Cancer made a strong commitment to advancing interprofessional research across the disciplinary spectrum by creating the new Nursing and Allied Health Research and Knowledge Translation (NAHRKT) department this year. What is unique about nursing and allied health is that we bring a distinctive perspective informed by practice expertise and an approach to research that guides knowledge generation toward relevant and meaningful problems. The NAHRKT department will strengthen our capacity at BC Cancer to generate new knowledge, enhance the impact of research, and support innovation in patient- and family-centred care. In this session, we will provide an overview of the NAHRKT department, explore research and KT resources and programs, and discuss opportunities for engaging in research and knowledge mobilization initiatives at BC Cancer.

Learning Objectives:

1. Learn about the role of NAHRKT at BC Cancer in supporting interprofessional research and knowledge mobilization
2. Explore resources and programs available to facilitate nursing and allied health research and KT
3. Review practice-based and collaborative research
4. Discuss opportunities to strengthen research capacity among nurses and allied health clinicians and trainees

Time	Topic	Speaker(s)
11:00am - 11:05am	Welcome & Introductions	Dr. Leah Lambert
11:05am – 11:30am	Nursing & Allied Health Research and Knowledge Translation Overview	Andrea Knox Dr. Maria Torrejon
11:30am – 11:50am	Practice-Based Research Challenge Outcomes	Jagbir Kaur
11:50am – 12:10pm	Collaborative Research Partnerships	Dustin Mackay
12:10am – 12:25pm	Facilitated Discussion- Supporting Pathways to Success	Grace Cole Caroline Pollock
12:25am – 12:30pm	Session wrap-up	Dr. Fuchsia Howard Scott Beck

Pharmacy Oncology Session

Friday, November 19, 2021

11:00am – 12:30pm

Moderator: Lynne Nakashima, Mario de Lemos, Rose-Marie Reddy

This session is focused on topics of interest to oncology pharmacy care providers and other health care professionals interested in new cancer treatment medications being introduced into practice at BC cancer. In this session, we will learn about new treatments for ovarian cancer, prostate cancer and chronic lymphocytic leukemia. We will also take a few minutes to celebrate the 30th Anniversary of the Cancer Drug Manual.

Learning Objectives:

Coming down the PARP(inhibitor) line: Niraparib for ovarian cancer

1. Review management of ovarian cancer and place in therapy for PARP inhibitors (PARPi)
2. Describe the evidence for niraparib in first and subsequent line treatment of ovarian cancer
3. Provide recommendations for toxicity monitoring and assessment

Prostate Cancer Update – Enzalutamide and Apalutamide in Metastatic Castration Sensitive Prostate Cancer

1. Review evidence for enzalutamide and apalutamide in mCSPC
2. Compare agents funded for use in mCSPC
3. Outline goals of drug therapy used to treat mCSPC

Acalabrutinib: a new generation Bruton’s tyrosine kinase (BTK) inhibitor for CLL

1. Review Chronic Lymphocytic Leukemia (CLL) as a disease state along with current disease management
2. Describe the evidence for use of acalabrutinib as first line treatment and in relapsed CLL
3. Compare and contrast available Bruton Tyrosine Kinase (BTK) inhibitors for CLL: acalabrutinib vs. ibrutinib

Time	Topic	Speaker(s)
11:00 - 11:05 am	Welcome and Cancer Drug Manual 30th Anniversary	Lynne Nakashima
11:05-11:30 am	Coming down the PARP (inhibitor) line: Niraparib for ovarian cancer	Andrew Pool
11:30-11:55 am	Prostate Cancer Update – Enzalutamide and Apalutamide in Metastatic Castration Sensitive Prostate Cancer	Jennifer Truong
11:55-12:25 pm	Acalabrutinib: a new generation Bruton’s tyrosine kinase (BTK) inhibitor for CLL	Rose-Marie Reddy
12:25-12:30 pm	Closing Remarks	Lynne Nakashima

Sarcoma Tumour Group

Friday, November 19, 2021

11:00am – 12:30pm

Moderator: Dr. Christine Simmons

This year has once again provided challenges of COVID as well as further identifying past and present systemic racism within our society. I would like to encourage us all to consider how our goals in of the areas of clinical care, education, research, and process improvement align with the Indigenous Cancer Plan set out by leadership.

Learning Objectives:

1. identify one study/advance/technique that has impressed you in terms of outcomes
2. provide a brief summary on this study
3. how does this relate to the BC Cancer population

Time	Topic	Speaker(s)
11:00am – 11:10am	Medical Oncology Sarcoma update	Dr. Ying Wang
11:10am – 11:20pm	Paediatric Oncology Sarcoma update	Dr. Deyell
11:20am – 11:30 pm	Orthopedic Oncology Sarcoma update	Dr. Paul Clarkson
11:30am – 11:40pm	Radiation Oncology Sarcoma update	Dr. Caroline Holloway
11:40am – 11:50pm	Surgical Oncology Sarcoma update	Dr. Andrea MacNeill
11:50am – 12:00pm	Translational Science Sarcoma update	<i>To be confirmed</i>
12:00pm – 12:10pm	Interventional radiology sarcoma update	<i>To be confirmed</i>
12:10pm – 12:20pm	Check-in/check-up: How is the Sarcoma TG performing	Dr. Christine Simmons
12:20pm – 12:30pm	Discussion	

Gender Identities & Sexual Orientations: Making Cancer Care Safe for Everyone

Friday, November 19th, 2021

11:00am – 12:30pm

Moderator: Antony Porcino

Sexual orientation and gender identity/expression (SOGIE) minority patients have poorer health outcomes arising from less-frequent access of healthcare due to past negative health care experiences, lack of SOGIE-appropriate patient supports, and fear of disrespect or lack of safety. This can be compounded by suppressive ethnicity and cultural/religious norms. Adverse health outcomes for SOGIE patients in cancer care have been specifically identified in research.

In this session, we will start with a brief outline of key statistics and barriers in cancer care for patients from this community. The majority of the time will then be spent exploring composite case studies. We will wrap up with a brief introduction to the available resources and activities of the SOGIE Working Group, followed by a Q&A session with the audience.

Learning Objectives:

1. To understand the safety and equity barriers experienced by SOGIE persons
2. To be able to apply basic safety techniques to address key issues experienced by SOGIE persons
3. To understand where to find additional training, resources, and support materials

Time	Topic	Speaker(s)
11:00 – 11:10am	Welcome & Introductions	Antony Porcino
11:10 – 11:20am	SOGIE definitions. Why this is everyone's issue. Key barriers, issues, research	J Rivera Jen Nuk
11:20 – 11:25am	Patient partner presentation	Rachel Dsilva
11:25 – 12:10pm	Case studies review and discussion: planning for a safe encounter environment (breakout groups, then group debrief)	
12:10 – 12:15pm	Available resources & the SOGIE Working Group	
12:15 – 12:30pm	Q&A	

Breakout Sessions – 1:00PM

BC Cancer Research Stream – PM Session

***Non- accredited session**

Friday, November 19, 2021

1:00pm – 2:30pm

Moderator: Kevin Sauve

BC Cancer Research contributes to improving the lives of patients through the integration of basic biomedical research, genomics, clinical trials, health services research, cancer surveillance, population health, and the development and delivery of innovative new technology, programs, and interventions. This year, the focus is on Early Career Researchers and research trainees, with presentations about the new and innovative projects of these new and emerging investigators.

Time	Topic	Speaker(s)
1:00pm – 1:30pm	<i>To be confirmed</i>	GrasPoDs talks
1:30pm – 2:00pm	<i>To be confirmed</i>	Andrew Roth
2:00pm – 2:30pm	<i>To be confirmed</i>	Rachel Murphy

Breast Tumour Group – PM Session

Friday, November 19, 2021

1:00pm – 2:30pm

Moderator: Dr. Stephen Chia

Time	Topic	Speaker(s)
1:00pm – 1:45pm	Breast Radiation Oncology	Dr. Pauline Truong Theordora Koulis
1:45pm – 2:30pm	Breast Cancer patients and HCP Update	Dr. Intan Schrader Dr. Sophie Sun Dr. Stephen Chia

Lung Cancer Update BC Cancer

Friday, November 19, 2021

1:00pm – 2:30pm

Moderator: Dr. Barb Melosky

Thoracic Oncology continues to evolve. To serve our patients the best, a truly multidisciplinary team is needed. In today’s session we will be reviewing the new Focus Panel and the recent experience with it. A fast biomarker testing platform Biocartis will be discussed. As the biobank continues to accrue, an update will be provided. The treatment of unresectable Stage III NSCLC has changed dramatically leading to improved patient survival. The BC Cancer experience in this patient subgroup will be presented. As well, we will discuss guidelines on follow up recommendations of these patients to achieve optimal care. Finally we will be updated in the practice of radiation oncologists in the province of British Columbia

Learning Objectives:

1. Review the new Focus Panel
2. Discuss the Biocartis Pilot Project
3. Update on the Lung Cancer Biobank
4. Present the BC Cancer Experience in unresectable Stage III NSCLC
5. Explore guidelines for follow up of unresectable Stage III NSCLC
6. Highlight the practice of thoracic radiation oncologists in BC

Time	Topic	Speaker(s)
1:00pm – 1:15pm	Update on the Focus Panel	Dr. Stephen Yip
1:15pm – 1:30pm	The Biocartis Pilot Project	Dr. Deepu Alex
1:30pm – 1:45pm	The Lung Cancer Biobank	Dr. Diana Ionescu
1:45pm – 2:00pm	BC Cancer experience in unresectable Stage III NSCLC	Dr. MarieHelene Denault
2:00pm – 2:15pm	Guidelines on follow up for unresectable Stage III NSCLC	Dr. Jenny Ko
2:15pm – 2:30pm	Update on Thoracic Radiation Oncology at BC Cancer	Dr. Benjamin Mou

Gastrointestinal Tumour Group

Friday, November 19th, 2021

1:00pm – 2:30pm

Moderator: Dr. Dan Renouf

Session will involve discussion of GI Surgical Oncology and opportunities for further integration.

Learning Objectives:

1. Understand GI surgical oncology structure and opportunities for integration
2. Learn about ongoing GI clinical trials at BC Cancer
3. Discuss creation of a provincial GI clinical trials network

Time	Topic	Speaker(s)
1:00pm – 1:40pm	GI Surgical Oncology: Updates and Opportunities for further Integration	Carl Brown Surgical Tumor Group chairs
1:40pm – 1:50pm	Break	Dr. Alan Bates
1:50pm – 2:30pm	Provincial GI Clinical Trials	Jon Loree

Gynecology Tumour Group

Friday, November 19th, 2021

1:00pm – 2:30pm

Moderator: Dr. Yvette Drew

This session will introduce new members of the gyne cancer multi-disciplinary BC Cancer team; highlighting their interests and roles. This will provide opportunities for virtual networking after the session and stimulate discussions as to how we can work together better to improve patient care as a group. Specific talks will then cover novel cancer treatment approaches and therapies from surgery, radiation and medical oncology, including local, national and international initiatives. We will look at precision and personalised medicine approaches in the rare, under researched cancer - vulval cancer. The scientific talk will discuss metabolomics in cancer, including how they relate to ovarian cancer treatment resistance. The session will discuss and review novel radiotherapy techniques in cervical cancer and cover key updates in systemic therapies from the recent European Society of Medical Oncology (ESMO) 2021 meeting.

There will be opportunities during each talk to ask questions to the speaker panel

Learning Objectives:

1. Be better informed and understand key updates from the pivotal GYNE trials results presented at ESMO 2021
2. Increase their knowledge of novel brachtherapy techniques in the management of gynecological cancers
3. Have a better understanding of the field of cancer metabolomics and a greater awareness of research being undertaken in BC Cancer Centers relating to ovarian cancer metabolomics
4. Understand the key differences in biology and disease course in HPV-related and P53 mutated vulval cancers.

Time	Topic	Speaker(s)
1:00pm – 1:05pm	Welcome	Dr. Yvette Drew
1:05 pm – 1:15pm	Introducing the new BC Cancer 'Team Gyne' members	Dr Anna Tinker
1:15 pm – 1:35pm	Stratification of vulvar squamous cell carcinoma by HPV and p53 status to direct care	Dr Amy Jamieson
1:35 pm – 1:55pm	Unlocking therapy resistance in ovarian cancer: check your metabolism	Dr Julian Lum
1:55 pm – 2:15pm	Interstitial vaginal brachytherapy in British Columbia: cooperation, individualization and customization	Dr Francois Bachand
2:15 pm – 2:25pm	Targeted systemic therapies take home messages from ESMO 2021	Dr Alannah Smrke
2:25 pm – 2:30pm	Closing remarks	Dr. Yvette Drew

Medical Physicist Session – (This session is for BC Cancer Medical Physicists only)

***Non- accredited session**

Friday, November 19, 2021

1:00pm – 2:30pm

Moderator: Wayne Beckham

Forum open to BC Cancer Medical Physicists Only. Discussion will involve professional issues.

The Path to Enhanced Nursing Practice - The Role of Professional Practice Nursing in Oncology

Friday, November 19, 2021

1:00pm – 2:05pm

Moderator: Joy Bunsko

Do you have ideas for advancing oncology nursing practice at BC Cancer? This interactive session will invite you to participate in sharing your thoughts, ideas and focus for nursing in the upcoming year. Virtual question and answer periods will allow you to arrive at priorities that will shape the work Professional Practice Nursing will complete in 2022!

Learning Objectives:

1. Understand the role of Professional Practice Nursing
2. Identify the areas of structure and focus
3. Collaborate with your nursing colleagues to set priorities

Time	Topic	Speaker(s)
1:00pm –1:10pm	Introduction to Professional Practice Nursing	Ruby Gidda Theressa Zapach
1:10pm – 1:30pm	Nursing Practice Structure	Jeevan Dosanjh Joy Bunsko
1:30pm –1:55pm	Come on Down! You're the Next Contestant on "This or That!"	
1:55pm –2:05pm	We're not done yet!	

Optimizing physical function throughout cancer treatments: Emerging evidence

Friday, November 19th, 2021

1:00pm – 2:30pm

Moderator: Jen Edgecombe

Reduced physical function is common during and after cancer treatments. Research shows that higher physical function can lead to improved treatment outcomes, increased quality of life and in some cases may influence treatment decisions and options. This session draws on emerging evidence from research and clinical practice. The speakers will draw upon both research and practical knowledge and discuss optimizing physical function throughout cancer treatment using targeted nutrition, structured exercise, physiotherapy and Speech & Language Pathology interventions. Dr. Carla Prado is a Professor at the University of Alberta with a research program that focuses on targeted nutrition interventions for the prevention and treatment of low muscle mass in patients with cancer. Dr. Prado will discuss emerging evidence for targeted nutrition interventions. Dr. Kristin Campbell is a Professor at the Department of Physical Therapy at UBC and leads a research program that focuses on the role of exercise in cancer prevention, rehabilitation and survivorship. Dr. Campbell recently led the first international guidelines on exercise for individuals with bone metastases and will discuss these recommendations. Hilary Cochrane and Lisa Kuhn are Speech and Language Pathologists at BC Cancer and will focus on swallowing function during head and neck cancer treatments. Finally, Janet Sprague is a Physiotherapist and Certified Lymphedema Therapist and will discuss the role of physiotherapy for the maintenance of function during cancer treatment and improving function in cancer recovery.

Learning Objectives:

1. Understand evidence-based interventions from multiple disciplines that can optimize physical function
2. Review emerging evidence for exercise recommendations for people with bone metastases
3. Explore clinical practice considerations and the role of SLP and Physiotherapy during cancer treatments and recovery

Time	Topic	Speaker(s)
1:00pm – 1:05pm	Introduction	Jen Edgecombe
1:05pm – 1:25pm	Improving physical function through targeted nutrition interventions	Dr. Carla Prado
1:25pm – 1:45pm	Exercise for people with bone metastases: New international	Dr. Kristin Campbell
1:45pm – 2:05pm	Optimizing long term swallow function during head and neck cancer treatments	Hilary Cochrane & Lisa Kuhn
2:05pm – 2:25pm	The role of physiotherapy in cancer recovery	Janet Sprague
2:25pm – 2:30pm	Wrap up and final questions	Jen Edgecombe

Advanced topics in Psycho-oncology and Palliative Care: Artificial Intelligence, Pregnancy, Death and the Law

Friday, November 19, 2021

1:00pm – 2:30pm

Moderator: Dr. Alan Bates

This session explores both new and challenging topics in Psycho-oncology and Palliative Care. Dr. Pippa Hawley, who has led BC Cancer's Pain & Symptom Management/Palliative Care service since its creation in 1997, will detail highlights from her new book *Lap of Honour* and provide invaluable tips in how to help patients live well with dying. The middle of a clinical crisis is never the best time to realize one doesn't know much about laws that govern the crucial next steps of care. Drawing from her recent publication in *BCMJ*, Dr. Jenny Laidlaw will outline core features of and need-to-know differences between the Mental Health Act, Healthcare Consent Act, and Adult Guardianship Act. Melanie McDonald, Patient & Family Counseling lead for Vancouver Cancer Centre, will draw on a case and her recent publication in the *Journal of Psychosocial Oncology* to describe challenges in self-disclosure of pregnancy when working with a patient who has experienced fertility loss. Dr. John-Jose Nunez, a UBC Psychiatry resident and Masters student in Computer Science, will finish the session by outlining his recent work at BC Cancer using natural language processing (a form of artificial intelligence) to predict both survival and need for psychosocial intervention.

Learning Objectives:

1. Explore needs of patients at end-of-life both within and outside clinical settings
2. Understand key differences between the Mental Health Act, Healthcare Consent Act, and Adult Guardianship Act
3. Review challenges related to self-disclosure and patients with fertility loss as a pregnant therapist
4. Learn how advances in artificial intelligence may allow better prediction of survival and identify need for psychosocial interventions before clinician referral.

Time	Topic	Speaker(s)
1:00pm – 1:05	Welcome and introduction	Dr. Alan Bates
1:05pm – 1:25	Helping patients live well with dying	Dr. Pippa Hawley
1:25pm – 1:45	Get your Acts together: Mental Health Act, Healthcare Consent Act, Adult Guardianship	Dr. Jenny Laidlaw
1:45pm – 2:05pm	How do I work with fertility loss as a pregnant therapist? A case study and discussion about pregnancy self-disclosure in the oncology	Melanie McDonald
2:05pm – 2:45pm	Predicting survival and need for psychosocial interventions using artificial	Dr. John-Jose Nunez
2:45pm – 2:30pm	Wrap-up and final questions	Dr. Alan Bates

Plenary: BC Cancer Awards

Friday, November 19, 2021

2:30pm –3:30pm

Moderators: Dr. Ursula Lee and Dr. Christine Simmons

Time	Topic	Speaker(s)
2:30pm – 2:35pm	Doctors of BC Terry Fox Medal	Dr. Kim Nguyen Chi Dr. Matthew Chow
2:35pm – 2:50pm	Terry Fox Medal – Lecture	Dr. Karen Gelmon
2:50pm – 3:15pm	BC Cancer Excellence Awards <ul style="list-style-type: none"> ➤ Patient Care Champion – Patient Nominated ➤ Patient Care Champion – Staff Nominated ➤ Unsung Hero ➤ Workplace Inspiration ➤ Team Innovation and Discovery in Action ➤ Teamwork and Collaboration in Action Poster Awards <ul style="list-style-type: none"> ➤ Population Health & Health Services ➤ Translation/Clinical Research ➤ Biology and Informatics ➤ Patient Experience and Supportive Care Outstanding Trainee Paper Competition 2020 Winners <ul style="list-style-type: none"> ➤ Clinical/Translational ➤ Basic/Translational ➤ Health Services and Population Health Research 	Dr. Kim N. Chi Heather Findlay
3:15pm – 3:30pm	BC Cancer Summit Remarks	Dr. Ursula Lee Dr. Christine Simmons

Saturday, November 20, 2021

Plenary: Family Practice Oncology Network (FPON) General Practitioner Oncology (GPO) Day

Saturday, November 20, 2021

8:30am – 12:40pm

Moderator: Dr. Sian Shuel, Dr. Cathy Clelland

Time	Topic	Facilitator	Specialist
8:30am – 8:40am	Welcome and Introductions	Dr. Sian Shuel	
8:40am – 9:40am	What's New in Systemic Therapy for the GPO TBC	Dr. Sian Shuel	Dr. Megan Tesch
9:40am – 9:50am	Break / Networking		
9:50am – 10:50am	Immunotherapy Related Endocrine Toxicities for the GPO	Dr. Sally MacDonald	Dr. Sabrina Gill
10:50am – 11:00am	Break / Networking		
11:00am – 12:00pm	Less Common but Relevant Immunotherapy Related Toxicities for the GPO	Dr. Elizabeth Ewart	Dr. Michael Humphries
12:00pm – 12:10pm	Close and Evaluations	Dr. Cathy Clelland	
12:10pm – 12:40pm.	Open Platform / Breakout Rooms for Networking	Dr. Sian Shuel	